"Payviders" are responsible for the cost of avoidable readmissions and emergency room visits, but they lose sight of patients once they go home.
|Videos|March 17, 2022
- MHE March 2022
- Volume 32
- Issue 3
Aaron Glatt of Mount Sinai Addresses the Major Concern of Obesity on COVID-19
Author(s)Briana Contreras
Aaron Glatt, MD, Chairman of the Department of Medicine and Chief of Infectious Diseases/Hospital Epidemiologist at Mount Sinai South Nassau and Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.
Advertisement
Articles in this issue
over 4 years ago
The Cost Burden of Alzheimer'sover 4 years ago
Frequent and Feared. But Can Dementia Be Avoided?over 4 years ago
Cancer Mortality is Decreasing in the U.S.over 4 years ago
New TEFCA Framework Brings Some Clarity to Interoperability Pushover 4 years ago
Fourth Shot is Recommended for the Immunocompromisedover 4 years ago
New COVID-19 Vaccines are in Late-stage Trialsover 4 years ago
Insurers and COVID-19 TestsAdvertisement
Related to this article
Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Jamilia Sherls, DNP, says health systems should track vaccine coverage closely and look to AAP schedules if federal guidance isn't evidence-based.
Model N's Jesse Mendelsohn explains why drug manufacturers argued that a 340B rebates instead of upfront discounts will avoid an overlapping maximum fair price and 340B discounts
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The payvider blind spot: When clinical visibility ends but financial risk continues
2
Quick Q&A: Jenny Goins on bringing PBM-style transparency to the medical side of benefits
3
Bronchiectasis is more common in the U.S. than a decade ago, study finds
4
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.
5